Copyright Reports & Markets. All rights reserved.

Global Vector-Based RNAi Market Research Report 2021

Request for Sample of this report
Buy now

1 Vector-Based RNAi Market Overview

  • 1.1 Product Overview and Scope of Vector-Based RNAi
  • 1.2 Vector-Based RNAi Segment by Type
    • 1.2.1 Global Vector-Based RNAi Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 siRNA Design
    • 1.2.3 siRNA Vectors
    • 1.2.4 Custom siRNA Construction
  • 1.3 Vector-Based RNAi Segment by Application
    • 1.3.1 Vector-Based RNAi Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospitals
    • 1.3.3 Speciality Clinics
  • 1.4 Global Vector-Based RNAi Market Size Estimates and Forecasts
    • 1.4.1 Global Vector-Based RNAi Revenue 2016-2027
    • 1.4.2 Global Vector-Based RNAi Sales 2016-2027
    • 1.4.3 Vector-Based RNAi Market Size by Region: 2016 Versus 2021 Versus 2027

2 Vector-Based RNAi Market Competition by Manufacturers

  • 2.1 Global Vector-Based RNAi Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Vector-Based RNAi Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Vector-Based RNAi Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Vector-Based RNAi Manufacturing Sites, Area Served, Product Type
  • 2.5 Vector-Based RNAi Market Competitive Situation and Trends
    • 2.5.1 Vector-Based RNAi Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Vector-Based RNAi Players Market Share by Revenue
    • 2.5.3 Global Vector-Based RNAi Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Vector-Based RNAi Retrospective Market Scenario by Region

  • 3.1 Global Vector-Based RNAi Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Vector-Based RNAi Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Vector-Based RNAi Market Facts & Figures by Country
    • 3.3.1 North America Vector-Based RNAi Sales by Country
    • 3.3.2 North America Vector-Based RNAi Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Vector-Based RNAi Market Facts & Figures by Country
    • 3.4.1 Europe Vector-Based RNAi Sales by Country
    • 3.4.2 Europe Vector-Based RNAi Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Vector-Based RNAi Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Vector-Based RNAi Sales by Region
    • 3.5.2 Asia Pacific Vector-Based RNAi Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Vector-Based RNAi Market Facts & Figures by Country
    • 3.6.1 Latin America Vector-Based RNAi Sales by Country
    • 3.6.2 Latin America Vector-Based RNAi Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Vector-Based RNAi Sales by Country
    • 3.7.2 Middle East and Africa Vector-Based RNAi Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Vector-Based RNAi Historic Market Analysis by Type

  • 4.1 Global Vector-Based RNAi Sales Market Share by Type (2016-2021)
  • 4.2 Global Vector-Based RNAi Revenue Market Share by Type (2016-2021)
  • 4.3 Global Vector-Based RNAi Price by Type (2016-2021)

5 Global Vector-Based RNAi Historic Market Analysis by Application

  • 5.1 Global Vector-Based RNAi Sales Market Share by Application (2016-2021)
  • 5.2 Global Vector-Based RNAi Revenue Market Share by Application (2016-2021)
  • 5.3 Global Vector-Based RNAi Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Merck & Co.
    • 6.1.1 Merck & Co. Corporation Information
    • 6.1.2 Merck & Co. Description and Business Overview
    • 6.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Merck & Co. Product Portfolio
    • 6.1.5 Merck & Co. Recent Developments/Updates
  • 6.2 Phio Pharmaceutical
    • 6.2.1 Phio Pharmaceutical Corporation Information
    • 6.2.2 Phio Pharmaceutical Description and Business Overview
    • 6.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Phio Pharmaceutical Product Portfolio
    • 6.2.5 Phio Pharmaceutical Recent Developments/Updates
  • 6.3 Quark Pharmaceuticals
    • 6.3.1 Quark Pharmaceuticals Corporation Information
    • 6.3.2 Quark Pharmaceuticals Description and Business Overview
    • 6.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Quark Pharmaceuticals Product Portfolio
    • 6.3.5 Quark Pharmaceuticals Recent Developments/Updates
  • 6.4 Thermo Fisher Scientific
    • 6.4.1 Thermo Fisher Scientific Corporation Information
    • 6.4.2 Thermo Fisher Scientific Description and Business Overview
    • 6.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Thermo Fisher Scientific Product Portfolio
    • 6.4.5 Thermo Fisher Scientific Recent Developments/Updates
  • 6.5 Silence Therapeutics
    • 6.5.1 Silence Therapeutics Corporation Information
    • 6.5.2 Silence Therapeutics Description and Business Overview
    • 6.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Silence Therapeutics Product Portfolio
    • 6.5.5 Silence Therapeutics Recent Developments/Updates
  • 6.6 Qiagen NV
    • 6.6.1 Qiagen NV Corporation Information
    • 6.6.2 Qiagen NV Description and Business Overview
    • 6.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Qiagen NV Product Portfolio
    • 6.6.5 Qiagen NV Recent Developments/Updates
  • 6.7 Ionis Pharmaceutical
    • 6.6.1 Ionis Pharmaceutical Corporation Information
    • 6.6.2 Ionis Pharmaceutical Description and Business Overview
    • 6.6.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Ionis Pharmaceutical Product Portfolio
    • 6.7.5 Ionis Pharmaceutical Recent Developments/Updates
  • 6.8 Dicerna Pharmaceuticals
    • 6.8.1 Dicerna Pharmaceuticals Corporation Information
    • 6.8.2 Dicerna Pharmaceuticals Description and Business Overview
    • 6.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Dicerna Pharmaceuticals Product Portfolio
    • 6.8.5 Dicerna Pharmaceuticals Recent Developments/Updates
  • 6.9 Arrowhead Pharmaceuticals
    • 6.9.1 Arrowhead Pharmaceuticals Corporation Information
    • 6.9.2 Arrowhead Pharmaceuticals Description and Business Overview
    • 6.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Arrowhead Pharmaceuticals Product Portfolio
    • 6.9.5 Arrowhead Pharmaceuticals Recent Developments/Updates
  • 6.10 Arcturus Therapeutics
    • 6.10.1 Arcturus Therapeutics Corporation Information
    • 6.10.2 Arcturus Therapeutics Description and Business Overview
    • 6.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Arcturus Therapeutics Product Portfolio
    • 6.10.5 Arcturus Therapeutics Recent Developments/Updates
  • 6.11 Alnylam Pharmaceuticals
    • 6.11.1 Alnylam Pharmaceuticals Corporation Information
    • 6.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Description and Business Overview
    • 6.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Alnylam Pharmaceuticals Product Portfolio
    • 6.11.5 Alnylam Pharmaceuticals Recent Developments/Updates

7 Vector-Based RNAi Manufacturing Cost Analysis

  • 7.1 Vector-Based RNAi Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Vector-Based RNAi
  • 7.4 Vector-Based RNAi Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Vector-Based RNAi Distributors List
  • 8.3 Vector-Based RNAi Customers

9 Vector-Based RNAi Market Dynamics

  • 9.1 Vector-Based RNAi Industry Trends
  • 9.2 Vector-Based RNAi Growth Drivers
  • 9.3 Vector-Based RNAi Market Challenges
  • 9.4 Vector-Based RNAi Market Restraints

10 Global Market Forecast

  • 10.1 Vector-Based RNAi Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Vector-Based RNAi by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Vector-Based RNAi by Type (2022-2027)
  • 10.2 Vector-Based RNAi Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Vector-Based RNAi by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Vector-Based RNAi by Application (2022-2027)
  • 10.3 Vector-Based RNAi Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Vector-Based RNAi by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Vector-Based RNAi by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    siRNA Design
    siRNA Vectors
    Custom siRNA Construction

    Segment by Application
    Hospitals
    Speciality Clinics

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Merck & Co.
    Phio Pharmaceutical
    Quark Pharmaceuticals
    Thermo Fisher Scientific
    Silence Therapeutics
    Qiagen NV
    Ionis Pharmaceutical
    Dicerna Pharmaceuticals
    Arrowhead Pharmaceuticals
    Arcturus Therapeutics
    Alnylam Pharmaceuticals

    Buy now